Letter: PNPLA3, metabolic syndrome and NAFLD status in obese subjects – authors’ reply

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|42|5|630-631

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.5, 2015-09, pp. : 630-631

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Letter: PNPLA3, metabolic syndrome and NAFLD status in obese subjects

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 5, 2015-09 ,pp. : 630-630

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: PNPLA3 and alcoholic liver disease – an alert to methodological limitations. Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 594-594

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: HIV‐associated NAFLD – more questions than answers? Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 9, 2015-05 ,pp. : 912-913

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: metabolic syndrome in patients with coeliac disease on a gluten‐free diet – authors' reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 8, 2015-04 ,pp. : 796-796

John Wiley & Sons Inc

Access to resources Recommend Favorite

PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non‐obese subjects with hepatitis C

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 10, 2015-05 ,pp. : 939-948

John Wiley & Sons Inc

Access to resources Recommend Favorite